# Aymeric Sallin

> Aymeric Sallin is a Series D investor at +ND Capital backing Biotechnology and Medical. See 21 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [+ND Capital](https://shizune.co/investors/profile/nd-capital)
- Location: San Francisco, United States
- Total investments: 21
- Last investment: Feb 2018
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/aymeric-sallin-9b859/

Aymeric Sallin is a Series D investor at +ND Capital in San Francisco focused on Biotechnology and Medical. Aymeric Sallin is the Founder and Managing Director of NanoDimension.Aymeric has led investments in Crocus Technology, Xtellus, and Selecta Biosciences and currently represents NanoDimension on the Board of Crocus Technology and Selecta Biosciences.Aymeric has received the "NSTI Fellow Award" for outstanding contributions to theadvancement of the international nanotechnology community.Prior to NanoDimension, Aymeric was a strategy consultant at Bain & Company focusing on the high-tech industry.Aymeric received a Masters Degree in Physical Engineering from the Federal Institute of Technology (EPFL) in Lausanne, Switzerland and currently serves on the Advisory Board of the Physics Department.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 14% |
| Medical | 2 | 10% |
| Electronics | 2 | 10% |
| Health Care | 2 | 10% |
| Software | 1 | 5% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 3 | 14% |
| Series B | 2 | 10% |
| Series E | 2 | 10% |
| Funding Round | 2 | 10% |
| Series A | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 24% |
| Switzerland | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| H55 | H55 is developing certified technology solutions to make aviation clean, quite, efficient, affordable and ultimative autonomous through the use of electric propulsion systems and sensor technology. |  |  | Feb 20, 2018 |  |
| H55 | H55 is developing certified technology solutions to make aviation clean, quite, efficient, affordable and ultimative autonomous through the use of electric propulsion systems and sensor technology. |  |  | Feb 20, 2018 |  |
| Tarveda Therapeutics | Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $30M | Series D | Feb 02, 2017 |  |
| Tarveda Therapeutics | Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $30M | Series D | Feb 02, 2017 |  |
| Selecta Biosciences | Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $38M | Series E | Sep 08, 2015 |  |
| Selecta Biosciences | Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $38M | Series E | Sep 08, 2015 |  |
| Crocus Technology | Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications. | $21M | Series E | Jun 16, 2015 |  |
| Tarveda Therapeutics | Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $21M | Series B | Jan 07, 2015 |  |
| Tarveda Therapeutics | Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $21M | Series B | Jan 07, 2015 |  |
| Selecta Biosciences | Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $20M | Private Equity | Oct 15, 2014 |  |

10 of 21 investments shown.

## Co-investors
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 11 deals together
- [+ND Capital](https://shizune.co/investors/profile/nd-capital) — VC Fund, 11 deals together
- [NanoDimension](https://shizune.co/investors/profile/nanodimension) — VC Fund, 10 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [I2BF Global Ventures](https://shizune.co/investors/profile/i2bf-global-ventures) — VC Fund, 4 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 4 deals together

## About +ND Capital

VC Fund · San Mateo, United States

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

5 contacts available at +ND Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Aymeric Sallin | Founder and CEO | https://shizune.co/investors/profile/aymeric-sallin |
| Eric Moessinger | Partner | https://shizune.co/investors/profile/eric-moessinger |
| Jonathan Nicholson | Director | https://shizune.co/investors/profile/jonathan-nicholson |
| Kirill Kuzmichev | Principal | https://shizune.co/investors/profile/kirill-kuzmichev |
| Louis-Philippe Lalonde | Entrepreneur-In-Residence | https://shizune.co/investors/profile/louis-philippe-lalonde-fab9 |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Aymeric Sallin invest in?

Aymeric Sallin invests primarily in Biotechnology, Medical and Electronics startups, most often at Series D and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Aymeric Sallin last invest?

The most recent investment recorded for Aymeric Sallin closed in Feb 2018. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co